Clinical phenotypes of epigenetic biomarker positive versus biomarker negative postpartum depression
Journal of Affective Disorders · 2026-12 · 414 · 122284
DOI: 10.1016/j.jad.2026.122284 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Affective Disorders, 2026-12. Verfasst von Elizabeth S Wenzel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, USA. Electronic address: rds3uy@uvahealth.org. Hauptthemen laut MEDLINE: Depression, Postpartum, Epigenesis, Genetic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, National Institute of Mental Health.
Themen: Depression
Abstract (Originalsprache)
Postpartum depression (PPD) can be predicted by biomarkers of 3rd trimester methylation at two estrogen-responsive genes (TTC9B, HP1BP3), but the mechanism(s) by which these epigenetic changes lead to PPD are unknown. We investigated whether clinical characteristics (psychiatric histories, depression onset, stress/anxiety/trauma) differ between those with (BM+) and without (BM-) these biomarkers of PPD risk. Participants (N = 206) completed clinical diagnostic interviews and stress, anxiety, and trauma questionnaires at up to 7 visits during pregnancy and postpartum. Biomarker status was determined using 3rd trimester blood samples. Linear mixed effects models compared outcomes between biomarker groups (positive/negative). Mediation models assessed the average causal mediation effect of anxiety on the relationship between biomarker status and PPD. BM+ individuals were more likely to 1) have a prior history of generalized anxiety (X2 = 10.06, p = .003) and bipolar II disorder (X2 = 7.68, p = .01), 2) develop PPD (X2 = 3.97, p = .04), and 3) be depressed during both pregnancy and postpartum (X2 = 6.52, p = .02). BM+ individuals scored higher on the perinatal anxiety screening scale (PASS, p = .006), perceived stress scale (PSS, p = .001), and state-trait anxiety inventory (STAI)-trait subscale (p = .02). Anxiety outcomes on the PASS (95% CI: 0.01-0.10, p = .004), PSS (95% CI: 0.007-0.10, p = .03), and STAI-State (95% CI: -0.001-0.06, p = .06) mediated the relationship between biomarker status and PPD development. Findings suggest distinct clinical phenotypes between BM+ and BM- PPD, with BM+ individuals displaying significantly higher anxiety/stress, which may contribute to their higher risk of developing PPD. This presents an opportunity to investigate mechanisms in more homogenous groups based on biomarker status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, USA. Electronic address: rds3uy@uvahealth.org.
- University of Ottawa Institute of Mental Health Research, The Royal, Ottawa, ON, Canada.
- Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, USA.
Förderung
- NIMH NIH HHS
- National Institute of Mental Health
Zitieren
APA
Wenzel, E. S., Kaminsky, Z., Pennycuff, K., Pangtey, M., & Payne, J. L. (2026). Clinical phenotypes of epigenetic biomarker positive versus biomarker negative postpartum depression. Journal of Affective Disorders, 414, 122284. https://doi.org/10.1016/j.jad.2026.122284
Vancouver
Wenzel ES, Kaminsky Z, Pennycuff K, Pangtey M, Payne JL. Clinical phenotypes of epigenetic biomarker positive versus biomarker negative postpartum depression. Journal of Affective Disorders. 2026;414:122284. doi:10.1016/j.jad.2026.122284
BibTeX
@article{Wenzel2026,
author = {Wenzel, Elizabeth S and Kaminsky, Zachary and Pennycuff, Kayla and Pangtey, Meeta and Payne, Jennifer L},
title = {Clinical phenotypes of epigenetic biomarker positive versus biomarker negative postpartum depression},
journal = {Journal of Affective Disorders},
year = {2026},
volume = {414},
pages = {122284},
doi = {10.1016/j.jad.2026.122284}
}
EUVIMED